Search Results 31-40 of 17369 for GLP-1 secretion

  1. Female infertility - Diagnosis & treatment - Mayo Clinic

    ... release at the time of ovulation. Concerns exist ... On average, how many days pass between the beginning of one menstrual cycle and the beginning of your next ...

  2. Michael D. Jensen, M.D. - Mayo Clinic Faculty Profiles

    Whether a person gains or loses fat in one body region rather than another is determined by how well the fat cells in those regions accept and release fat ...

  3. Management of obesity within hepatology clinics - Mayo Clinic

    Anti-obesity medications · Glucagon-like peptide 1 (GLP-1) receptor agonists. These agents can lead to significant weight loss. According to Dr. · Sodium-glucose ...

  4. Obesity - Diagnosis and treatment - Mayo Clinic

    Also approved by the FDA is a class of drugs known as glucagonlike peptide 1 agonists, also called GLP-1 agonists. Some of these medicines are approved ...

  5. Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes - Mayo Clinic

    Participation eligibility · Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects ...

  6. A Study to Evaluate the Effect of 1,25-Dihydroxyvitamin D3 to Treat Insulin Secretion and Muscle Strength in Pre-diabetics - Mayo Clinic

    The purpose of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the pancreas and glucose utilization by skeletal muscle, as well as to ...

  7. Liraglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic

    This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide injection is also used together with a reduced-calorie diet and proper ...

  8. Lixisenatide (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Lixisenatide is used together with diet and exercise to help control your blood sugar. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. This ...

  9. Longitudinal Effects of Diabetes-Associated Variation in TCF7L2 on Glucagon and Insulin Secretion in Non-Diabetic Humans - Mayo Clinic

    The goal of this study is to determine the role of postprandial glucagon suppression and insulin secretion in the progression of glucose intolerance in people ...

  10. Type 2 diabetes - Symptoms and causes - Mayo Clinic

    Both type 1 and type 2 diabetes can begin during childhood and adulthood. ... Podcast: How do GLP-1s work? Show more products ... Sugar in the bloodstream causes ...